Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

References for PMC Articles for PubMed (Select 22688511)

1.

Ephs and ephrins in cancer: ephrin-A1 signalling.

Beauchamp A, Debinski W.

Semin Cell Dev Biol. 2012 Feb;23(1):109-15. doi: 10.1016/j.semcdb.2011.10.019. Epub 2011 Oct 25. Review.

2.

Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma.

Pullen NA, Anand M, Cooper PS, Fillmore HL.

J Neurooncol. 2012 Feb;106(3):461-71. doi: 10.1007/s11060-011-0691-5. Epub 2011 Aug 21.

PMID:
21858729
3.

Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway.

Anand M, Van Meter TE, Fillmore HL.

J Neurooncol. 2011 Sep;104(3):679-87. doi: 10.1007/s11060-011-0549-x. Epub 2011 Feb 27.

PMID:
21359852
4.

Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis.

Dunaway CM, Hwang Y, Lindsley CW, Cook RS, Wu JY, Boothby M, Chen J, Brantley-Sieders DM.

Mol Cell Biol. 2011 Feb;31(3):404-16. doi: 10.1128/MCB.00667-10. Epub 2010 Dec 6.

5.

Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas.

Zhang Y, Zhan H, Xu W, Yuan Z, Lu P, Zhan L, Li Q.

Pathol Res Pract. 2011 Jan 15;207(1):24-9. doi: 10.1016/j.prp.2010.10.003. Epub 2010 Nov 18.

PMID:
21087829
6.

Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.

Gialeli C, Theocharis AD, Karamanos NK.

FEBS J. 2011 Jan;278(1):16-27. doi: 10.1111/j.1742-4658.2010.07919.x. Epub 2010 Nov 19. Review.

PMID:
21087457
7.

Comparative expression pattern of Matrix-Metalloproteinases in human glioblastoma cell-lines and primary cultures.

Hagemann C, Anacker J, Haas S, Riesner D, Schömig B, Ernestus RI, Vince GH.

BMC Res Notes. 2010 Nov 10;3:293. doi: 10.1186/1756-0500-3-293.

8.

Pro-neurotrophins secreted from retinal ganglion cell axons are necessary for ephrinA-p75NTR-mediated axon guidance.

Marler KJ, Poopalasundaram S, Broom ER, Wentzel C, Drescher U.

Neural Dev. 2010 Nov 2;5:30. doi: 10.1186/1749-8104-5-30.

9.

Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells.

Alford S, Watson-Hurthig A, Scott N, Carette A, Lorimer H, Bazowski J, Howard PL.

Cancer Cell Int. 2010 Oct 27;10:41. doi: 10.1186/1475-2867-10-41.

10.

ADAM13 induces cranial neural crest by cleaving class B Ephrins and regulating Wnt signaling.

Wei S, Xu G, Bridges LC, Williams P, White JM, DeSimone DW.

Dev Cell. 2010 Aug 17;19(2):345-52. doi: 10.1016/j.devcel.2010.07.012.

11.

Crystal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations.

Singla N, Goldgur Y, Xu K, Paavilainen S, Nikolov DB, Himanen JP.

Biochem Biophys Res Commun. 2010 Sep 3;399(4):555-9. doi: 10.1016/j.bbrc.2010.07.109. Epub 2010 Aug 1.

12.

Physiology and pathophysiology of matrix metalloproteases.

Klein T, Bischoff R.

Amino Acids. 2011 Jul;41(2):271-90. doi: 10.1007/s00726-010-0689-x. Epub 2010 Jul 18. Review.

13.

Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells.

Lu DY, Leung YM, Cheung CW, Chen YR, Wong KL.

Biochem Pharmacol. 2010 Oct 15;80(8):1201-9. doi: 10.1016/j.bcp.2010.06.046. Epub 2010 Jul 6.

PMID:
20615395
14.

Architecture of Eph receptor clusters.

Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, Mensinga A, Lackmann M, Nikolov DB, Dhe-Paganon S.

Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10860-5. doi: 10.1073/pnas.1004148107. Epub 2010 May 26.

15.

Cytoplasmic relaxation of active Eph controls ephrin shedding by ADAM10.

Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, Sabet O, Grabenbauer M, Ting AY, Saftig P, Bastiaens PI, Lackmann M.

PLoS Biol. 2009 Oct;7(10):e1000215. doi: 10.1371/journal.pbio.1000215. Epub 2009 Oct 13.

16.

Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Roy R, Yang J, Moses MA.

J Clin Oncol. 2009 Nov 1;27(31):5287-97. doi: 10.1200/JCO.2009.23.5556. Epub 2009 Sep 8. Review.

17.

EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.

Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY, Kim DG.

Int J Cancer. 2010 Feb 15;126(4):940-9. doi: 10.1002/ijc.24798.

PMID:
19642143
18.

Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.

Himanen JP, Goldgur Y, Miao H, Myshkin E, Guo H, Buck M, Nguyen M, Rajashankar KR, Wang B, Nikolov DB.

EMBO Rep. 2009 Jul;10(7):722-8. doi: 10.1038/embor.2009.91. Epub 2009 Jun 12.

19.

Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis.

Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M, Iwakura Y, Suda T, Matsuo K.

J Biol Chem. 2009 May 22;284(21):14637-44. doi: 10.1074/jbc.M807598200. Epub 2009 Mar 19.

20.

The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Wykosky J, Debinski W.

Mol Cancer Res. 2008 Dec;6(12):1795-806. doi: 10.1158/1541-7786.MCR-08-0244. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk